Skip to main content
Premium Trial:

Request an Annual Quote

Cepheid Shares Jump 8.9 Percent After Investment Bank Upgrades Stock

NEW YORK, Jan. 5 (GenomeWeb News) - UBS today upgraded Cepheid's stock to 'Buy' from 'Neutral' claiming changes in the company's valuation make the stock more attractive.


Shares in Cepheid were up 8.9 percent, or $.79, to $9.75 in mid-afternoon trading.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more